| Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059] | Technology appraisal guidance | TBC |
| Abaloparatide for treating osteoporosis in postmenopausal women [ID882] | Technology appraisal guidance | TBC |
| Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185] | Technology appraisal guidance | TBC |
| Abicipar pegol for treating wet age-related macular degeneration ID1533 | Technology appraisal guidance | TBC |
| Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768] | Technology appraisal guidance | TBC |
| Acute Respiratory Infection in over 16s: Initial assessment and management | NICE guideline | |
| Acute respiratory infection in over 16s: initial assessment and management, including using virtual wards | Quality standard | |
| Adrenal insufficiency: acute and long-term management | NICE guideline | |
| Alcohol-mediated perivascular renal denervation for resistant hypertension | Interventional procedures guidance | |
| Algorithm-based remote monitoring of heart failure risk data in people with cardiac implantable electronic devices | Diagnostics guidance | |
| Alzheimer's disease (early) - gantenerumab [ID6142] | Technology appraisal guidance | TBC |
| Arimoclomol for treating Niemann-Pick disease Type C [ID1312] | Highly specialised technology | TBC |
| Artificial intelligence (AI) software to help clinical decision making in stroke | Diagnostics guidance | |
| Artificial Intelligence for dermatology - skin cancer: reduce referrals by early detection of benign skin lesions (provisional title) | Diagnostics guidance | TBC |
| Artificial intelligence technologies to aid contouring for radiotherapy treatment planning: early value assessment | Health technology evaluation | |
| Artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment | Health technology evaluation | TBC |
| Asthma: diagnosis, monitoring and chronic asthma management | NICE guideline | |
| Asunercept for treating glioblastoma [1301] | Technology appraisal guidance | TBC |
| Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701 | Technology appraisal guidance | TBC |
| Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101] | Technology appraisal guidance | TBC |
| Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730] | Technology appraisal guidance | TBC |
| Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213] | Technology appraisal guidance | TBC |
| ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093] | Technology appraisal guidance | TBC |
| Atogepant for preventing migraine [ID5090] | Technology appraisal guidance | TBC |
| Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000] | Technology appraisal guidance | TBC |
| Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707] | Technology appraisal guidance | TBC |
| Avapritinib for treating advanced systemic mastocytosis ID3770 | Technology appraisal guidance | TBC |
| Avelumab for previously treated platinum-resistant ovarian cancer ID1497 | Technology appraisal guidance | TBC |
| Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261] | Technology appraisal guidance | TBC |
| AZD 3152 for preventing COVID-19 [ID6282] | Technology appraisal guidance | TBC |
| Baricitinib for treating juvenile idiopathic arthritis in children and young people aged 1 to 17 [ID6143] | Technology appraisal guidance | TBC |
| Baricitinib for treating severe alopecia areata [ID3979] | Technology appraisal guidance | TBC |
| Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108] | Technology appraisal guidance | TBC |
| Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701] | Technology appraisal guidance | |
| Belumosudil for treating chronic graft versus host disease after 2 or more lines of systemic therapy [ID4021] | Technology appraisal guidance | |
| Belzutifan for previously treated advanced renal cell carcinoma [ID6154] | Technology appraisal guidance | TBC |
| Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932] | Technology appraisal guidance | |
| Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093] | Technology appraisal guidance | TBC |
| Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145] | Technology appraisal guidance | |
| Bimatoprost implant for treating open angle glaucoma or ocular hypertension in people who are unsuitable for topical treatments [ID6180] | Technology appraisal guidance | TBC |
| Bimekizumab for treating active psoriatic arthritis [ID4009] | Technology appraisal guidance | |
| Bimekizumab for treating axial spondyloarthritis [ID6245] | Technology appraisal guidance | |
| Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134] | Technology appraisal guidance | TBC |
| Biodegradable subacromial spacer insertion for rotator cuff tears | Interventional procedures guidance | |
| Bipolar disorder: assessment and management (extraordinary review) | NICE guideline | TBC |
| Birch bark extract for treating skin wounds associated with dystrophic and junctional epidermolysis bullosa [ID1505] | Technology appraisal guidance | |
| Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768] | Technology appraisal guidance | TBC |
| Breast cancer guidelines | NICE guideline | TBC |
| Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ] | Technology appraisal guidance | TBC |
| Burosumab for treating X-linked hypophosphataemia in adults [ID3822] | Technology appraisal guidance | TBC |
| Cabotegravir injections for preventing HIV-1 in adults and young people ID6255 | Technology appraisal guidance | TBC |
| Cabozantinib for previously treated differentiated thyroid cancer unsuitable for or refractory to radioactive iodine [ID4046] | Technology appraisal guidance | |
| Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243] | Technology appraisal guidance | |
| Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma [ID3940] | Technology appraisal guidance | TBC |
| Cabozantinib with nivolumab for untreated advanced renal cell carcinoma [ID6184] | Technology appraisal guidance | TBC |
| Caesarean birth - morbidly adherent placenta | NICE guideline | |
| Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653] | Technology appraisal guidance | TBC |
| Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114] | Technology appraisal guidance | TBC |
| Cardiovascular disease: risk assessment and reduction, including lipid modification - Escalation of Therapy | NICE guideline | |
| Cedazuridine-decitabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable [ID6135] | Technology appraisal guidance | TBC |
| Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639] | Technology appraisal guidance | TBC |
| Cemiplimab with chemotherapy for untreated advanced or metastatic non-small-cell lung cancer [ID3949] | Technology appraisal guidance | TBC |
| Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failure | NICE guideline | TBC |
| Chronic obstructive pulmonary disease in adults update | Quality standard | TBC |
| Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259] | Technology appraisal guidance | TBC |
| Clopidogrel genotype testing after ischaemic stroke or transient ischaemic attack | Diagnostics guidance | |
| COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment | Health technology evaluation | TBC |
| Colon cancer (adjuvant) - irinotecan [ID379] | Technology appraisal guidance | TBC |
| Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826] | Technology appraisal guidance | TBC |
| Cryotherapy for Chronic Rhinitis | Interventional procedures guidance | |
| Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 to 17 [ID5104] | Technology appraisal guidance | |
| Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088] | Technology appraisal guidance | TBC |
| Daprodustat for treating anaemia in people with chronic kidney disease [ID3987] | Technology appraisal guidance | |
| Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748] | Technology appraisal guidance | TBC |
| Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843] | Technology appraisal guidance | TBC |
| Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when stem cell transplant is unsuitable [ID4014] | Technology appraisal guidance | TBC |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297 | Technology appraisal guidance | TBC |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297 | Technology appraisal guidance | |
| DCVax-L for treating newly diagnosed glioblastoma multiforme [ID836] | Technology appraisal guidance | TBC |
| Diabetes - buccal insulin [ID311] | Technology appraisal guidance | TBC |
| Diabetes guidelines | NICE guideline | TBC |
| Diabetic retinopathy | NICE guideline | |
| Diabetic retinopathy - ruboxistaurin [ID382] | Technology appraisal guidance | TBC |
| Digital health technologies to help manage symptoms of psychosis and prevent relapse: early value assessment | Health technology evaluation | |
| Digital pulmonary rehabilitation technologies for adults with chronic obstructive pulmonary disease: early value assessment | Health technology evaluation | |
| Digital technologies for managing low back pain: early value assessment | Health technology evaluation | |
| Digitally enabled technologies to support treatment with weight-management medication in specialist weight-management services: early value assessment | Health technology evaluation | |
| Digitally enabled weight management programmes to support treatment with weight management medication (alternative service model): early value assessment | Health technology evaluation | |
| Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222] | Technology appraisal guidance | TBC |
| Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [ID3968] | Technology appraisal guidance | |
| Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314] | Technology appraisal guidance | TBC |
| Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055] | Technology appraisal guidance | TBC |
| Dupilumab for treating eosinophilic oesophagitis in people 12 years and over [ID5107] | Technology appraisal guidance | TBC |
| Dupilumab for treating prurigo nodularis [ID4054] | Technology appraisal guidance | |
| Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263] | NICE guideline | TBC |
| Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068] | Technology appraisal guidance | TBC |
| Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID5081] | Technology appraisal guidance | TBC |
| Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer ID6220 | Technology appraisal guidance | TBC |
| Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer [ID4031] | Technology appraisal guidance | TBC |
| Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725] | Technology appraisal guidance | |
| Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076] | Technology appraisal guidance | TBC |
| Early and locally advanced breast cancer: diagnosis and management - further surgery (update) | NICE guideline | TBC |
| Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170] | Technology appraisal guidance | |
| Efgartigimod for treating generalised myasthenia gravis [ID4003] | Technology appraisal guidance | |
| Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060] | Technology appraisal guidance | TBC |
| Elacestrant for treating postmenopausal hormone receptor-positive HER2-negative advanced or metastatic breast cancer after 1 or 2 endocrine treatments ID6225 | Technology appraisal guidance | TBC |
| Elranatamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID4026] | Technology appraisal guidance | |
| Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction [ID3945] | Technology appraisal guidance | |
| Empagliflozin for treating chronic kidney disease ID6131 | Technology appraisal guidance | |
| Endometriosis: diagnosis and management - diagnosing endometriosis | NICE guideline | |
| Endometriosis: diagnosis and management - surgical management if fertility is a priority | NICE guideline | |
| Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma | Interventional procedures guidance | TBC |
| Endoscopic duodenal mucosal resurfacing for type 2 diabetes | Interventional procedures guidance | TBC |
| Endoscopic gastric plication for severe obesity | Interventional procedures guidance | |
| Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845] | Technology appraisal guidance | |
| Epcoritamab for treating relapsed or refractory large B-cell lymphoma after 2 or more systemic treatments [ID4045] | Technology appraisal guidance | |
| Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica | Interventional procedures guidance | TBC |
| Epilepsies in children, young people and adults (extraordinary review) | NICE guideline | TBC |
| Epilepsies in children, young people and adults (update) | Quality standard | |
| ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623] | Technology appraisal guidance | TBC |
| Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058] | Technology appraisal guidance | TBC |
| Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333] | Technology appraisal guidance | TBC |
| Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812] | Technology appraisal guidance | |
| Etrasimod for treating moderately to severely active ulcerative colitis [ID5091] | Technology appraisal guidance | |
| Etrolizumab for previously treated moderately to severely active Crohn's disease [ID3965] | Technology appraisal guidance | TBC |
| Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 years and over [ID2704] | Technology appraisal guidance | |
| Exagamglogene autotemcel for treating sickle cell disease [ID4016] | Technology appraisal guidance | |
| Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015] | Technology appraisal guidance | |
| Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests | Diagnostics guidance | TBC |
| Extracorporeal carbon dioxide removal for acute respiratory failure | Interventional procedures guidance | |
| Falls: assessment and prevention in older people and people 50 and over at higher risk (update) | NICE guideline | |
| Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (Review of TA756) [ID5115] | Technology appraisal guidance | TBC |
| Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651] | Technology appraisal guidance | |
| Fertility problems: assessment and treatment | NICE guideline | |
| Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071] | Technology appraisal guidance | TBC |
| Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B ID4032 | Technology appraisal guidance | TBC |
| Filgotinib for treating moderately to severely active Crohn's disease [ID6236] | Technology appraisal guidance | TBC |
| Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous treatment (Review of TA613) [ID6307] | Technology appraisal guidance | TBC |
| Fosdenopterin for treating molybdenum cofactor deficiency type A ID6264 | Technology appraisal guidance | TBC |
| Foslevodopa-foscarbidopa for treating Parkinson's disease with motor symptoms [ID3876] | Technology appraisal guidance | |
| Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988] | Technology appraisal guidance | |
| Gefapixant for treating refractory or unexplained chronic cough [ID3789] | Technology appraisal guidance | TBC |
| GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509) | Medical technologies guidance | TBC |
| GID-MT563 NPi-200 for pupillary light reflex in critical care patients | Medical technologies guidance | TBC |
| GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain | Medical technologies guidance | TBC |
| GID-MT575 GaitSmart rehabilitation exercise programme for gait and mobility issues | Medical technologies guidance | |
| Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243] | Technology appraisal guidance | TBC |
| Glaucoma - lerdelimumab (CAT-152) [ID383] | Technology appraisal guidance | TBC |
| Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments [ID3970] | Technology appraisal guidance | |
| Harmful gambling: identification, assessment and management | NICE guideline | |
| High dose rate brachytherapy using non-sealed rhenium for non-melanoma skin cancer | Interventional procedures guidance | |
| High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis | Interventional procedures guidance | TBC |
| Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627] | Technology appraisal guidance | TBC |
| Human alpha1-proteinase inhibitor for treating emphysema ID856 | Highly specialised technology | TBC |
| Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes | Technology appraisal guidance | TBC |
| Ibrutinib for treating relapsed or refractory follicular lymphoma [1251] | Technology appraisal guidance | TBC |
| Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251] | Technology appraisal guidance | TBC |
| Ibrutinib for untreated mantle cell lymphoma [ID1221] | Technology appraisal guidance | TBC |
| Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547] | Technology appraisal guidance | |
| Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma in people who have received at least 3 prior therapies [ID1442] | Technology appraisal guidance | TBC |
| Implanting a baroreceptor stimulation device for resistant hypertension | Interventional procedures guidance | TBC |
| Indoor air quality at home | Quality standard | TBC |
| Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529] | Technology appraisal guidance | TBC |
| Infection prevention and control update | Quality standard | TBC |
| Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992] | Technology appraisal guidance | TBC |
| Insertion of neo-chordae into the beating heart for mitral regurgitation | Interventional procedures guidance | TBC |
| Intrapartum care for healthy women and babies (update) | NICE guideline | |
| Intravascular lithotripsy for calcified arteries in peripheral arterial disease | Interventional procedures guidance | |
| Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889] | Technology appraisal guidance | TBC |
| Iptacopan for treating paroxysmal nocturnal haemoglobinuria ID6176 | Technology appraisal guidance | |
| Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067] | Technology appraisal guidance | TBC |
| Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834] | Technology appraisal guidance | |
| Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 mutation after at least 1 therapy [ID6164] | Technology appraisal guidance | |
| Ivosidenib with azacitidine for untreated IDH1-positive acute myeloid leukaemia [ID6198] | Technology appraisal guidance | |
| Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706] | Technology appraisal guidance | TBC |
| KardiaMobile 6L for measuring cardiac QT interval in people having antipsychotic medication: early value assessment | Diagnostics guidance | TBC |
| Kidney Cancer | NICE guideline | TBC |
| KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336 | Technology appraisal guidance | TBC |
| Kurin Lock for blood culture collection | Medical technologies guidance | |
| Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687] | Technology appraisal guidance | TBC |
| Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [ID4025] | Technology appraisal guidance | TBC |
| Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043] | Technology appraisal guidance | TBC |
| Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410] | Technology appraisal guidance | TBC |
| Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130] | Technology appraisal guidance | |
| Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930] | Technology appraisal guidance | TBC |
| Leriglitazone for treating andrenoleukodystrophy [ID3903] | Highly specialised technology | TBC |
| Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166] | Technology appraisal guidance | TBC |
| Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190] | Technology appraisal guidance | |
| Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [ID1444] | Technology appraisal guidance | TBC |
| Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic therapies [ID3943] | Technology appraisal guidance | |
| Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840] | Technology appraisal guidance | |
| Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657] | Technology appraisal guidance | TBC |
| Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44] | Technology appraisal guidance | TBC |
| Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43] | Technology appraisal guidance | TBC |
| Lung transplantation with ex-vivo perfusion | Interventional procedures guidance | TBC |
| Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340 | Technology appraisal guidance | TBC |
| Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872] | Technology appraisal guidance | TBC |
| Lymphovenous anastomosis at the time of axillary/inguinal lymph node dissection for the prevention of secondary lymphoedema | Interventional procedures guidance | |
| Managing common infections - antimicrobial prescribing guidelines | NICE guideline | TBC |
| Maralixibat for treating cholestatic pruritus in Alagille Syndrome ID3941 | Technology appraisal guidance | |
| Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818] | Technology appraisal guidance | TBC |
| Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075] | Technology appraisal guidance | TBC |
| Maternal and child nutrition | NICE guideline | |
| Melanoma (metastatic) - talimogene laherparepvec [ID508] | Technology appraisal guidance | |
| Meningitis (bacterial) and meningococcal disease : recognition, diagnosis and management | NICE guideline | |
| Meningitis (bacterial) and meningococcal disease : recognition, diagnosis and management (update) | Quality standard | |
| Menopause: diagnosis and management | NICE guideline | |
| Middle Meningeal Embolisation for Chronic Subdural Haematomas (CSDH) | Interventional procedures guidance | TBC |
| Mirikizumab for treating moderately to severely active ulcerative colitis [ID3973] | Technology appraisal guidance | TBC |
| Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527] | Technology appraisal guidance | TBC |
| Molnupiravir, remdesivir and tixagevimab plus cilgavimab for treating COVID-19 [ID6261] | Technology appraisal guidance | TBC |
| Momelotinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis [ID6141] | Technology appraisal guidance | |
| MRI guided focussed ultrasound for chronic pain | Interventional procedures guidance | TBC |
| MTX110 for untreated diffuse intrinsic pontine glioma [ID2695] | Technology appraisal guidance | TBC |
| Neonatal infection update | Quality standard | |
| Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363] | Technology appraisal guidance | |
| Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858] | Technology appraisal guidance | |
| Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194] | Technology appraisal guidance | TBC |
| Nirmatrelvir plus ritonavir for treating COVID-19 (Partial Rapid Review of TA878) [ID6262] | Technology appraisal guidance | |
| Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858] | Technology appraisal guidance | |
| Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048] | Technology appraisal guidance | TBC |
| Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629 | Technology appraisal guidance | TBC |
| Nivolumab-relatlimab for untreated unresectable or metastatic melanoma [ID1688] | Technology appraisal guidance | |
| Non-invasive skin closure devices for surgical incisions (MT775) | Medical technologies guidance | TBC |
| Novel home-testing devices for diagnosing obstructive sleep apnoea/hypopnoea syndrome | Diagnostics guidance | |
| Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195] | Technology appraisal guidance | TBC |
| NY-ESO-1 T-cells for treating synovial sarcoma ID1286 | Technology appraisal guidance | TBC |
| Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645] | Technology appraisal guidance | TBC |
| Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181] | Technology appraisal guidance | TBC |
| Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA598) [ID6191] | Technology appraisal guidance | |
| Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205] | Technology appraisal guidance | TBC |
| Olaparib in combination with bevacizumab for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy with bevacizumab [Review of TA693] [ID4066] | Technology appraisal guidance | |
| Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ] | Technology appraisal guidance | |
| Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann Pick disease type B and AB) [ID3913 ] | Technology appraisal guidance | |
| Omburtamab for treating relapsed neuroblastoma [ID1664] | Technology appraisal guidance | TBC |
| Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111] | Technology appraisal guidance | TBC |
| OrganOx metra for liver transplant [ID5116] | Technology appraisal guidance | TBC |
| Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120] | Technology appraisal guidance | |
| Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update) | NICE guideline | |
| Otilimab for treating moderate to severe rheumatoid arthritis [ID6171] | Technology appraisal guidance | TBC |
| Ovarian cancer QS update | Quality standard | TBC |
| Ovarian cancer: identifying and managing familial and genetic risk | NICE guideline | |
| Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089] | Technology appraisal guidance | TBC |
| Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739] | Highly specialised technology | TBC |
| Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721] | Highly specialised technology | TBC |
| Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513] | Technology appraisal guidance | TBC |
| Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658] | Technology appraisal guidance | TBC |
| Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976] | Technology appraisal guidance | TBC |
| Peezy Midstream for urine collection (MT446) | Medical technologies guidance | TBC |
| Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural
mesothelioma [ID1575] | Technology appraisal guidance | TBC |
| Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594 | Technology appraisal guidance | TBC |
| Pegcetacoplan for treating geographic atrophy [ID4041] | Technology appraisal guidance | |
| Pegunigalsidase alfa for treating Fabry disease [ID3904] | Technology appraisal guidance | |
| Pegzilarginase as an add-on treatment for arginase-1 deficiency [ID4029] | Highly specialised technology | TBC |
| Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907] | Technology appraisal guidance | TBC |
| Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency [ID4036] | Technology appraisal guidance | |
| Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696] | Technology appraisal guidance | TBC |
| Pembrolizumab with chemotherapy for treating HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma [ID4030] | Technology appraisal guidance | TBC |
| Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103] | Technology appraisal guidance | TBC |
| Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer [ID4034] | Technology appraisal guidance | TBC |
| Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861] | Technology appraisal guidance | TBC |
| Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112] | Technology appraisal guidance | TBC |
| Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948] | Technology appraisal guidance | TBC |
| Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118] | Technology appraisal guidance | TBC |
| Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814] | Technology appraisal guidance | TBC |
| Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873] | Technology appraisal guidance | TBC |
| Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667] | Technology appraisal guidance | TBC |
| Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742] | Technology appraisal guidance | |
| Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia | Interventional procedures guidance | |
| Percutaneous thrombectomy for massive pulmonary embolus | Interventional procedures guidance | |
| Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724] | Technology appraisal guidance | TBC |
| Pharyngeal electrical stimulation for neurogenic dysphagia | Interventional procedures guidance | |
| PillCam COLON 2 for investigation of the colon through direct visualisation | Diagnostics guidance | |
| Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975] | Technology appraisal guidance | TBC |
| Pneumonia: diagnosis and management (update) | NICE guideline | TBC |
| Port Delivery System with ranibizumab for treating wet age-related macular degeneration [ID3983] | Technology appraisal guidance | TBC |
| Pralsetinib for thyroid cancer [ID4018] | Technology appraisal guidance | TBC |
| QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) | Diagnostics guidance | TBC |
| Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia ID4042 | Technology appraisal guidance | TBC |
| Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder [ID5105] | Technology appraisal guidance | |
| Ravulizumab for treating generalised myasthenia gravis [ID4019] | Technology appraisal guidance | |
| Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056] | Technology appraisal guidance | |
| Rehabilitation for chronic neurological disorders including acquired brain injury | NICE guideline | |
| Relugolix for treating hormone-sensitive prostate cancer ID6187 | Technology appraisal guidance | TBC |
| Relugolix–estradiol–norethisterone acetate for treating pain associated with endometriosis [ID3982] | Technology appraisal guidance | |
| Removal, preservation and reimplantation of ovarian tissue to restore fertility after gonadotoxic treatment | Interventional procedures guidance | TBC |
| Renal cell carcinoma Pathways Pilot [ID6186] | Technology appraisal guidance | TBC |
| Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307) | Technology appraisal guidance | TBC |
| Ribociclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153] | Technology appraisal guidance | TBC |
| Rimegepant for treating acute migraine [ID1539] | Technology appraisal guidance | |
| Risankizumab for previously treated moderately to severely active ulcerative colitis in people aged 16 and over ID6209 | Technology appraisal guidance | TBC |
| Ritlecitinib for treating severe alopecia areata in people 12 years and over [ID4007] | Technology appraisal guidance | |
| Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601] | Technology appraisal guidance | TBC |
| Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496] | Technology appraisal guidance | TBC |
| Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596] | Technology appraisal guidance | TBC |
| Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092] | Technology appraisal guidance | TBC |
| Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100] | Technology appraisal guidance | TBC |
| Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (Review of TA611) [ID4069] | Technology appraisal guidance | |
| Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998] | Technology appraisal guidance | |
| Ruxolitinib for treating polycythaemia vera (review of TA356) [ID5106] | Technology appraisal guidance | TBC |
| Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033] | Technology appraisal guidance | TBC |
| Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention | Interventional procedures guidance | TBC |
| SACT | NICE guideline | TBC |
| School-based interventions: physical and mental health and wellbeing promotion | Quality standard | TBC |
| Sebelipase alfa for treating lysosomal acid lipase deficiency [ID737] | Highly specialised technology | TBC |
| Sebelipase alfa for treating Wolman disease [ID3995] | Highly specialised technology | |
| Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738] | Technology appraisal guidance | TBC |
| Secukinumab for treating moderate to severe hidradenitis suppurativa [ID4039] | Technology appraisal guidance | |
| Selective internal radiation therapy (SIRT) for neuroendocrine tumours metastatic to the liver | Interventional procedures guidance | |
| Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797] | Technology appraisal guidance | TBC |
| Selpercatinib for untreated advanced thyroid cancer with RET alterations [ID6132] | Technology appraisal guidance | |
| Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183] | Technology appraisal guidance | TBC |
| Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome [ID3947] | Technology appraisal guidance | |
| Sirolimus for treating angiofibroma from tuberous sclerosis complex in people 6 years and older [ID3990] | Technology appraisal guidance | TBC |
| Skin cancer update | Quality standard | |
| Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis ID6246 | Technology appraisal guidance | TBC |
| Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001] | Technology appraisal guidance | TBC |
| Somapacitan for treating growth hormone deficiency in children [ID6178] | Technology appraisal guidance | TBC |
| Sotatercept for treating pulmonary arterial hypertension ID6163 | Technology appraisal guidance | TBC |
| SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals) | Medical technologies guidance | TBC |
| Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668] | Technology appraisal guidance | |
| Spesolimab for treating acute generalised pustular psoriasis [ID3963] | Technology appraisal guidance | TBC |
| Stroke rehabilitation in adults | NICE guideline | |
| Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001] | Technology appraisal guidance | TBC |
| Surgical correction of hallux valgus using minimal access techniques | Interventional procedures guidance | |
| Surgical vessel sealing systems (MT798) | Medical technologies guidance | TBC |
| Suspected cancer update | Quality standard | |
| Suspected Sepsis: recognition, diagnosis and early management (update) | NICE guideline | TBC |
| Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus [ID1203] | Technology appraisal guidance | TBC |
| Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327] | Technology appraisal guidance | |
| Talacotuzumab for untreated acute myeloid leukaemia [ID1262] | Technology appraisal guidance | TBC |
| Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations [ID1342] | Technology appraisal guidance | |
| Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004] | Technology appraisal guidance | TBC |
| Targeted temperature management to improve neurological outcomes after cardiac arrest | Interventional procedures guidance | |
| Targeted-release budesonide for treating IgA nephropathy [ID1434] | Technology appraisal guidance | |
| Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401 | Technology appraisal guidance | TBC |
| Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441] | Technology appraisal guidance | TBC |
| Third molars (impacted) - prophylactic removal [ID898] | Technology appraisal guidance | TBC |
| Tirzepatide for managing overweight and obesity [ID6179] | Technology appraisal guidance | |
| Tirzepatide for treating type 2 diabetes [ID3938] | Technology appraisal guidance | |
| Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (MA review of TA554) [ID6290] | Technology appraisal guidance | |
| Tislelizumab for previously treated advanced oesophageal squamous cell cancer [ID4070] | Technology appraisal guidance | TBC |
| Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161] | Technology appraisal guidance | TBC |
| Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162] | Technology appraisal guidance | TBC |
| Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753] | Technology appraisal guidance | TBC |
| Tofacitinib for treating active ankylosing spondylitis [ID3865] | Technology appraisal guidance | |
| Total hip arthroplasty using the superpath approach for osteoarthritis | Interventional procedures guidance | TBC |
| Tralokinumab for treating moderate to severe atopic dermatitis [ID3734] | Technology appraisal guidance | TBC |
| Transfemoral carotid artery stent placement for asymptomatic extracranial carotid stenosis | Interventional procedures guidance | |
| Transition from children's to adults' services - update | Quality standard | |
| Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia | Interventional procedures guidance | |
| Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935] | Technology appraisal guidance | |
| Treatments for non-small-cell lung cancer [ID6234] | Technology appraisal guidance | |
| Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745] | Technology appraisal guidance | TBC |
| Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298] | Technology appraisal guidance | TBC |
| Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227] | Technology appraisal guidance | TBC |
| Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node positive early breast cancer | Diagnostics guidance | |
| Twin and triplet pregnancy - progesterone for preventing preterm birth | NICE guideline | |
| Type 2 diabetes in adults: management (medicines update) | NICE guideline | |
| Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733] | Technology appraisal guidance | TBC |
| Vadadustat for treating anaemia in people with chronic kidney disease [ID3821] | Technology appraisal guidance | TBC |
| Vaginal natural orifice transluminal endoscopic surgery for hysterectomy and adnexal surgery | Interventional procedures guidance | |
| Vamorolone for treating Duchenne muscular dystrophy [ID4024] | Technology appraisal guidance | |
| Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277] | Technology appraisal guidance | TBC |
| Velmanase alfa for treating alpha-mannosidosis [ID800] | Highly specialised technology | TBC |
| Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565 | Technology appraisal guidance | TBC |
| Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040] | Technology appraisal guidance | TBC |
| Vibegron for treating symptoms of overactive bladder ID6300 | Technology appraisal guidance | TBC |
| Virtual reality for treating agoraphobia and agoraphobic avoidance: early value assessment | Health technology evaluation | |
| Virtual Ward Platform Technologies for acute respiratory infections | Health technology evaluation | |
| Vitamin B12 deficiency in over 16s: diagnosis and management | NICE guideline | |
| Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425] | Technology appraisal guidance | TBC |
| Voxelotor for treating sickle cell disease [ID1403] | Technology appraisal guidance | TBC |
| VTS-270 for treating Niemann-Pick type C1 [ID1267] | Highly specialised technology | TBC |
| Waldenstrom's macroglobulinaemia - ibrutinib [ID884] | Technology appraisal guidance | |
| Weight Management: preventing, assessing and managing overweight and obesity (update) | NICE guideline | |
| Women's and reproductive health guidelines | NICE guideline | TBC |
| Zanubrutinib for treating chronic lymphocytic leukaemia [ID5078] | Technology appraisal guidance | |
| Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085] | Technology appraisal guidance | TBC |
| Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079] | Technology appraisal guidance | TBC |
| Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008] | Technology appraisal guidance | TBC |
| Zio XT for detecting cardiac arrhythmias | Medical technologies guidance | TBC |